셀리드

299660KOSDAQ

65.3 / 100

Reference Date: 2026-09-08

Financial Score20.0 / 40

News Sentiment21.3 / 25

Momentum17.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 42.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Cellid is a biopharmaceutical company with proprietary technologies CeliVax (cancer immunotherapy vaccine) and Ad5/35 (infectious disease prevention vaccine), developing six cancer immunotherapy vaccines including BVAC-C and BVAC-E6E7, as well as a COVID-19 vaccine. It is currently conducting Phase 1/2a and 3 clinical trials, and generates revenue through CMO/CDMO services and e-commerce sales, though no products are currently on the market.

Number of Employees

49people

Average Salary

49.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.95Industry Average 1.204.0Point

In line with industry avg

ROE

-19.25Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

9.75Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲112.3% (1-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲3.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -27.6% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
셀리드, 코로나 재확산 우려에 22%대 강세…백신주 부각[특징주]
셀리드 주가가 코로나19 재확산 우려로 인해 강세를 보이며 백신 관련주로 주목받고 있다.

Detailed Momentum

52-week position5.0Point

52w mid range (42%)

Current 2,385Won52-week high 4,19552-week low 1,025

1-month return6.0Point

1m +41.96% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

3 totalPositive 0Neutral 2Negative 1

Negative소송등의판결ㆍ결정(일정금액이상의청구)2026-08-14
Neutral반기보고서 (2026.06)2026-08-14
Neutral[기재정정]투자판단관련주요경영사항 (사업반환청구의 소 제기의 건)2026-08-13